OptiBiotix Health PLC Directorate Change (5854K)

TIDMOPTI

RNS Number : 5854K

OptiBiotix Health PLC

17 December 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Directorate Change

Appointment of Managing Director of OptiBiotix's prebiotic division

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the intended departure of Per Rehne as a director of OptiBiotix Health plc after working a 3 month notice period. Per will remain as a director of OptiBiotix's newly formed subsidiary, ProBiotix Health Limited following his departure from OptiBiotix. A further announcement will be made in due course.

The Board is pleased to announce the appointment of Frederic Narbel ("Fred") as Managing Director of OptiBiotix's prebiotic division containing its SweetBiotix, OptiBiotic and microbiome modulating technology platforms. Fred will join the OptiBiotix Board subject to completion of the normal regulatory due diligence.

Fred has 11 years' experience in medical products and speciality food ingredients, and is joining OptiBiotix from a position as Vice President of Sales for Nutrition Solutions at Agropur, a Canadian dairy company with annualised sales of $6.4 billion (2017), and 8,300 employees. Agropur manufactures and distributes functional ingredients and has extensive operations across Canada and the US.

Fred brings extensive experience of selling speciality food ingredients in international markets and has managed sales teams in China, the USA, Singapore and Europe. He has a good reputation of building business-to-business sales through commercial partnerships and working with manufacturers and distributors to rapidly grow sales revenues in international markets. Fred comes with a wide network of contacts in the high value speciality food ingredients industry and a strong track record of rapidly growing sales.

Fred has a Doctorate in Business Administration, and MBA, and is multilingual in English, French, Finnish and German. His experience of speciality food ingredients will help drive the commercialisation of OptiBiotix's growing pipeline of products across its SweetBiotix, OptiBiotic and microbiome modulating technology platforms.

Stephen O'Hara, CEO of OptiBiotix, commented: "Fred's experience and track record of growing business-to-business sales of speciality food ingredients to provide differentiated nutritional solutions brings added commercial and industry specific expertise to OptiBiotix. His network of contacts provides access to new international markets which we hope will help drive revenue growth from OptiBiotix's growing pipeline of products amongst its SweetBiotix, OptiBiotic and microbiome modulating platforms. This will add further revenue streams to the growing revenues from OptiBiotix's LP-LDL and SlimBiome products. This is all part of a wider strategy of developing multiple revenue streams from both consumer and pharmaceutical products across all OptiBiotix's technology platforms.

On behalf of the Board, I would like to thank Per for his hard work with OptiBiotix and look forward to working with him in his role as a non-executive director of ProBiotix Health."

For further information, please contact:

 
 OptiBiotix Health plc                                           www.optibiotix.com 
 Stephen O'Hara, Chief Executive                               Contact via Walbrook 
                                                                              below 
 
 Cairn Financial Advisers LLP (NOMAD)                            Tel: [phone] 
 Liam Murray / Jo Turner 
 
 finnCap (Broker)                                                Tel: [phone] 
 Geoff Nash/ Scott Mathieson / Kate Bannatyne 
  (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 
 Walbrook PR Ltd                    Tel: [phone] or [e-mail] 
 Anna Dunphy                                                     Mob: [phone] 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty five international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOAQZLFFVLFFFBE

(END) Dow Jones Newswires

December 17, 2018 02:01 ET (07:01 GMT)